Published in Nat Genet on October 08, 2006
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet (2009) 18.90
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol (2010) 5.35
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Mutations of the SLX4 gene in Fanconi anemia. Nat Genet (2011) 3.60
Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature (2013) 3.40
Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet (2011) 3.25
Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol (2014) 3.12
Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet (2011) 3.06
FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability. Mol Cell Biol (2008) 2.88
Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat (2008) 2.69
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Genetic susceptibility to breast cancer. Mol Oncol (2010) 2.52
Architecture of inherited susceptibility to common cancer. Nat Rev Cancer (2010) 2.14
PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res (2010) 2.07
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet (2009) 2.02
Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96
Interaction between the helicases genetically linked to Fanconi anemia group J and Bloom's syndrome. EMBO J (2011) 1.95
FANCJ is a structure-specific DNA helicase associated with the maintenance of genomic G/C tracts. J Biol Chem (2008) 1.93
The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection. J Biol Chem (2011) 1.91
The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. EMBO J (2007) 1.86
Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. Mol Cell (2009) 1.85
Realizing the promise of cancer predisposition genes. Nature (2014) 1.84
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet (2012) 1.84
Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet (2008) 1.82
Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest (2007) 1.80
Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol (2016) 1.76
Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet (2012) 1.76
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol (2015) 1.73
Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res (2008) 1.72
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst (2015) 1.70
A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res (2010) 1.68
Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res (2007) 1.61
G-quadruplex nucleic acids and human disease. FEBS J (2010) 1.58
Welcome the family of FANCJ-like helicases to the block of genome stability maintenance proteins. Cell Mol Life Sci (2009) 1.54
DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair. Mol Cell Biol (2007) 1.53
Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res (2010) 1.51
Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res (2011) 1.45
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer (2008) 1.45
Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res (2008) 1.44
FANCJ uses its motor ATPase to destabilize protein-DNA complexes, unwind triplexes, and inhibit RAD51 strand exchange. J Biol Chem (2009) 1.43
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden. Hered Cancer Clin Pract (2015) 1.40
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res (2007) 1.40
CANDID: a flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol (2008) 1.36
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res (2010) 1.29
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci (2012) 1.26
Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function. Oncogene (2009) 1.25
Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res (2007) 1.24
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
DNA helicase and helicase-nuclease enzymes with a conserved iron-sulfur cluster. Nucleic Acids Res (2012) 1.20
RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res (2010) 1.20
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer (2013) 1.19
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma (2008) 1.18
A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response. Nucleic Acids Res (2009) 1.16
Genetics of breast cancer: a topic in evolution. Ann Oncol (2015) 1.15
Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer. Breast Cancer Res Treat (2012) 1.15
The complex genetic landscape of familial breast cancer. Hum Genet (2013) 1.14
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate (2008) 1.12
Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer (2007) 1.12
Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis (2008) 1.11
Fanconi anemia proteins and endogenous stresses. Mutat Res (2009) 1.11
Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol (2011) 1.11
The Fanconi anemia pathway and ubiquitin. BMC Biochem (2007) 1.10
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One (2013) 1.10
Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass. Oncogene (2010) 1.10
Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res (2013) 1.09
Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One (2007) 1.08
Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer. PLoS Genet (2015) 1.08
Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med (2012) 1.07
Deep congenic analysis identifies many strong, context-dependent QTLs, one of which, Slc35b4, regulates obesity and glucose homeostasis. Genome Res (2011) 1.06
A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Res (2014) 1.05
FANCJ helicase uniquely senses oxidative base damage in either strand of duplex DNA and is stimulated by replication protein A to unwind the damaged DNA substrate in a strand-specific manner. J Biol Chem (2009) 1.04
Fanconi anemia group J mutation abolishes its DNA repair function by uncoupling DNA translocation from helicase activity or disruption of protein-DNA complexes. Blood (2010) 1.02
Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer (2014) 1.02
Parameterizing cell-to-cell regulatory heterogeneities via stochastic transcriptional profiles. Proc Natl Acad Sci U S A (2014) 1.01
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses. Biochim Biophys Acta (2014) 1.01
Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int (2013) 1.01
FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress. Curr Mol Med (2009) 1.00
Dissecting disease inheritance modes in a three-dimensional protein network challenges the "guilt-by-association" principle. Am J Hum Genet (2013) 1.00
Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. Curr Cancer Drug Targets (2009) 1.00
Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res (2010) 1.00
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. Eur J Hum Genet (2008) 1.00
Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. Cancer Res (2008) 1.00
Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract (2013) 0.99
Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol (2009) 0.98
Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 0.98
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res (2008) 0.97
Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet (2011) 0.97
CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res (2011) 0.97
Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Fam Cancer (2012) 0.96
Germline mutations and polymorphisms in the origins of cancers in women. J Oncol (2010) 0.96
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res (2007) 6.91